Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease

Dyslipidemia is common in chronic kidney disease (CKD). Despite statins, many patients fail to adequately lower lipids and remain at increased risk of cardiovascular disease. Selective ET(A) (endothelin-A) receptor antagonists reduce cardiovascular disease risk factors. Preclinical data suggest that...

Descripción completa

Detalles Bibliográficos
Autores principales: Farrah, Tariq E., Anand, Atul, Gallacher, Peter J., Kimmitt, Robert, Carter, Edwin, Dear, James W., Mills, Nicholas L., Webb, David J., Dhaun, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott, Williams & Wilkins 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635059/
https://www.ncbi.nlm.nih.gov/pubmed/31177906
http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.12919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635059/
https://www.ncbi.nlm.nih.gov/pubmed/31177906
http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.12919

Ejemplares similares